Proof-of-concept study of clinical use of blood-based MAVS biosensor in predicting immunotherapy response in SCLC patients
A simple, cheap blood test predicts which lung cancer patients will respond to immunotherapy, potentially sparing non-responders from ineffective treatment.
This proof-of-concept study demonstrated that a low-cost blood-based MAVS biosensor could distinguish SCLC patients who respond to chemo-immunotherapy from non-responders, with a 10-fold difference in serum MAVS levels. The portable platform costs ~$5/test, suggesting potential for point-of-care immunotherapy response prediction.
What the study was
- Study design
- Proof-of-concept clinical study
- Population
- SCLC patients undergoing chemo-immunotherapy ± radiotherapy
- Category
- Diagnostics
- Maturity
- Exploratory
- Journal
- Translational Oncology
Why it surfaced
Highly novel $5 biosensor for immunotherapy response prediction in SCLC. Small cohort limits score, but addresses a major unmet need in SCLC biomarker stratification.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.